Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Extracorporeal CO₂ elimination (ECCO₂R) is an integral part of modern intensive care medicine. It can be used to reduce the carbon dioxide (CO₂) content in the blood and, consequently, potentially lower the risk of ventilation-induced lung damage. The aim of the study was to investigate the safety and effectiveness of the multiECCO2R gas exchanger in patients with combined renal insufficiency and hypercapnia due to acute lung failure.
In this multicenter, prospective, interventional study, 28 patients were recruited and treated for up to 72 hours on the multiFiltrate (MFT)/MFT PRO with the multiECCO₂R gas exchanger under citrate or heparin anticoagulation. The clinical objective was to demonstrate that combined CVVHD/CVVHDF and multiECCO₂R treatment can reduce respiratory acidosis and the need for ventilation in patients with concomitant renal failure. The technical objective was to investigate how much CO₂ can be eliminated by the multiECCO2R gas exchanger in extracorporeal circulation. Study-specific parameters were documented at baseline and throughout the course of the treatment.
A total of 28 patients were included in the study. Among them, 18 patients received citrate anticoagulation and are presented here as preliminary data, while 10 patients received heparin anticoagulation and will be reported in the comprehensive study publication. The primary cause of acute renal failure (AKI stage 3, 100%) was sepsis (47.4%), and the primary cause of pulmonary failure was pneumonia (73.7%), SOFA score 13.5 ± 2.8. The results showed a significant reduction in paCO₂ values from 56.59 ± 6.98 mmHg (start of treatment) to 42.90 ± 7.21 mmHg (after 72 h; p=0.0028) with constant ventilation parameters and improved pH values (7.30 ± 0.07 - 7.43 ± 0.06; p=0.0226). Protective ventilation was ensured by an inspiratory pressure difference (driving pressure) of 16 ± 4 mbar and a tidal volume of 5 ± 1.3 mL/kg PBW (predicted body weight). Despite the maximum blood flow of 200 ml/min with citrate anticoagulation, the treatment resulted in a significant paCO₂ reduction. PCO₂ was 49 ± 9.8 mmHg before and 7 ± 3.4 mmHg after the gas exchanger (start of treatment), and the calculated CO₂ elimination remained largely constant over time.
The multiECCO₂R gas exchanger in combination with multiFiltrate is suitable for significantly reducing the CO₂ level in the blood. This is possible with relatively low blood flows, so that a Shaldon catheter is sufficient and large-bore cannulation can be avoided in selected patients. A comprehensive analysis of the study data is in preparation.
